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Rapid determination of an infective aetiology causing neurological inflammation in the cerebrospinal fluid can be challenging in
clinical practice. Post-surgical nosocomial infection is difficult to diagnose accurately, as it occurs on a background of altered cere-
brospinal fluid composition due to the underlying pathologies and surgical procedures involved. There is additional diagnostic diffi-
culty after external ventricular drain or ventriculoperitoneal shunt surgery, as infection is often caused by pathogens growing as
biofilms, which may fail to elicit a significant inflammatory response and are challenging to identify by microbiological culture.
Despite much research effort, a single sensitive and specific cerebrospinal fluid biomarker has yet to be defined which reliably dis-
tinguishes infective from non-infective inflammation. As a result, many patients with suspected infection are treated empirically
with broad-spectrum antibiotics in the absence of definitive diagnostic criteria. To begin to address these issues, we examined cere-
brospinal fluid taken at the point of clinical equipoise to diagnose cerebrospinal fluid infection in 14 consecutive neurosurgical
patients showing signs of inflammatory complications. Using the guidelines of the Infectious Diseases Society of America, six cases
were subsequently characterized as infected and eight as sterile inflammation. Twenty-four contemporaneous patients with
idiopathic intracranial hypertension or normal pressure hydrocephalus were included as non-inflamed controls. We measured 182
immune and neurological biomarkers in each sample and used pathway analysis to elucidate the biological underpinnings of any
biomarker changes. Increased levels of the inflammatory cytokine interleukin-6 and interleukin-6-related mediators such as oncos-
tatin M were excellent indicators of inflammation. However, interleukin-6 levels alone could not distinguish between bacterially
infected and uninfected patients. Within the patient cohort with neurological inflammation, a pattern of raised interleukin-17, inter-
leukin-12p40/p70 and interleukin-23 levels delineated nosocomial bacteriological infection from background neuroinflammation.
Pathway analysis showed that the observed immune signatures could be explained through a common generic inflammatory re-
sponse marked by interleukin-6 in both nosocomial and non-infectious inflammation, overlaid with a toll-like receptor-associated
and bacterial peptidoglycan-triggered interleukin-17 pathway response that occurred exclusively during infection. This is the first
demonstration of a pathway dependent cerebrospinal fluid biomarker differentiation distinguishing nosocomial infection from
background neuroinflammation. It is especially relevant to the commonly encountered pathologies in clinical practice, such as sub-
arachnoid haemorrhage and post-cranial neurosurgery. While requiring confirmation in a larger cohort, the current data indicate
the potential utility of cerebrospinal fluid biomarker strategies to identify differential initiation of a common downstream interleu-
kin-6 pathway to diagnose nosocomial infection in this challenging clinical cohort.
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Introduction
Neurological infection continues to pose a significant bur-
den of disease and is responsible for an estimated 20.4
million disability-adjusted life years globally (95% confi-
dence interval (CI) 17.4–23.4 million (Feigin et al.,
2019). Nosocomial neurological infection differs signifi-
cantly from community-acquired infection, as it usually
develops after neurosurgical or neurological interventions,
has a distinct bacteriological profile and by definition
occurs against a background neurological illness. These
all conspire to make early and accurate differential diag-
nosis difficult but mandatory for the optimal management
of these often critically ill patients (van de Beek et al.,
2010). Moreover, many acute neurological and neurosur-
gical conditions have a prominent inflammatory compo-
nent from central nervous system (CNS) damage, and it
is especially challenging to diagnose superimposed noso-
comial infection against a background of an already acti-
vated innate immune response (Tunkel et al., 2017). The
lack of accurate diagnostic tests at the point of clinical
equipoise is a critically important unmet need with
significant clinical and healthcare cost implications (Beer
et al., 2008; Dorresteijn et al., 2019; Mallucci et al.,
2019; Sorinola et al., 2019; Zervos and Walters, 2019).
Recent cranial neurosurgery is a major risk factor for
nosocomial ventriculitis or meningitis (van de Beek et al.,
2010). The risk varies significantly with surgical proced-
ure, duration and whether devices are implanted
(Kourbeti et al., 2015). The most common implanted
devices are either temporary external ventricular drains
(EVD) or permanent ventriculoperitoneal (VP) shunts for
controlling hydrocephalus (Fernández-Méndez et al.,
2019). Both EVD and VP shunt insertion carry a signifi-
cant risk of infection, with recent large UK prospective
studies showing rates of 9.3% in 495 EVD insertions
(Jamjoom et al., 2018) and 6% in 1594 first VP shunts
(Mallucci et al., 2019).
Nosocomial infection introduced by EVDs and VP
shunt surgery is particularly challenging to diagnose
against a background of significant neurological disease
and/or inflammation caused by recent surgery. The con-
ventional clinical symptoms and signs of community-
acquired neurological infection are unreliable, with the
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classic triad of fever/nuchal rigidity/altered mental status
or headache being only partially or fully present in 50–
95% of patients (van de Beek et al., 2010; Viallon et al.,
2016). Gram staining of CSF although rapid and highly
specific, has poor sensitivity for neurosurgical infections
with only 20% of healthcare-associated ventriculitis and
meningitis showing a positive CSF Gram stain (Srihawan
et al., 2016). While CSF culture remains the mainstay of
diagnosis, both EVD and VP shunt infections have simi-
lar bacteriological profiles, largely Staphylococcus aureus
and coagulase-negative Staphylococcus, which typically
cause a low-grade inflammation from within a biofilm
(Gutierrez-Murgas and Snowden, 2014), often making
bacteriological detection from CSF difficult. Not only
does bacterial culture have a high false-negative rate (up
to one third in some cases) (Wu et al., 2013), it usually
requires 24–48 h to generate definitive results, frequently
necessitating blind empirical interim antibiotic treatment.
Additionally, microbiological culture often yields false
positives due to contamination during sampling or fails
to result in the growth of any organism in partially re-
sponsive empirically pre-treated cases. The addition of
biochemical measures such as CSF glucose and protein
levels, C-reactive protein and procalcitonin to microbio-
logical and clinical factors have limited diagnostic value
for diagnosing nosocomial infection, because of the often
low-grade nature of the infecting pathogens resulting in
smaller bacteriological metabolic perturbations from nor-
mal (for reviews see Dorresteijn et al., 2019; Zervos and
Walters, 2019).
Promising results in the diagnosis of community-
acquired bacterial meningitis (Prasad et al., 2014;
Srinivasan et al., 2016) have generated considerable inter-
est in investigating a variety of inflammatory biomarkers
to diagnose nosocomial CSF infection. However, many of
these studies are based on retrospective case series and
do not always distinguish between CSF samples taken at
initial clinical diagnostic equipoise and later samples col-
lected after empirical or culture-positive treatments have
commenced. Many are diagnosed post hoc and although
automated group analysis is accurate for group prediction
(van Mourik et al., 2015), its positive predictive value
remains poor (van Mourik et al., 2012). Moreover, most
studies investigate single or small numbers of CSF factors,
with limited combinatorial analyses confounding the in-
vestigation of biologically plausible underlying signalling
mechanisms. A single study (Skar et al., 2019a) in a ro-
dent EVD model showed a trend towards a promising
pattern of interleukin (IL)-10, IL-1b, chemokine ligand 2
(CCL2) and CCL3, which differentiated infection from
inflammation.
In this prospective study, we examined a battery of
182 inflammatory and neurological markers in CSF
obtained from EVDs, shunts or via lumbar puncture at
the point of clinical diagnostic equipoise, across a spec-
trum of neurosurgical patients, to determine whether CSF
biomarkers can distinguish between inflammatory
processes due to infective and non-infective causes.
Uniquely, we then used a modified pathway analysis
method to examine the biological underpinnings of the
biomarker changes identified. We found that increased
levels of inflammatory cytokines related to IL-6 were
excellent indicators of inflammation, as was described
previously, but that they could not distinguish between
bacterially infected and uninfected patients. By perform-
ing a two-tiered statistical analysis, we show a potential
biomarker signature of diagnostic relevance, consisting of
raised IL-6 or oncostatin M (OSM) levels in the CSF for
detecting general CNS inflammation, and additionally
raised IL-17 together with raised IL-12p40 or IL-23 levels
as indicative of a bacterial cause for the inflammation.
Pathway analysis identified toll-like receptor (TLR) acti-
vation as the likely underlying signalling pathway dis-




Between March 2017 and March 2018, 38 patients in
whom CSF sampling was clinically indicated were con-
sented for additional donation and sampling of CSF
and serum for the purpose of this study. CSF samples
were obtained from the Wales Neurosciences Research
Tissue Bank (WNTRB Ethics Rec Ref: WA/19/0058;
Requisition No. 019). CSF samples were collected by
trained individuals as part of routine clinical care,
transferred on ice and centrifuged (4500 rpm, 10 min at
4C) to remove cells and debris within 30 min of collec-
tion. The acellular supernatant was then aliquoted
(300 ml) and frozen at 80C for storage in the
WNTRB until analysis.
Patients were categorized into three groups that were
mixed with respect to the underlying neurological condi-
tion (Table 1). Index patients were prospectively identi-
fied and categorized on the basis of clinical diagnostic
equipoise for nosocomial infection, and all underwent
CSF sampling (Supplementary Table 1). This sampling at
the point of equipoise was intentional, as this is the clin-
ical timepoint at which an investigation of biomarkers
for diagnostic utility is the most clinically relevant. This
group was later characterized into two diagnostic sub-
groups. Nosocomial infection (‘Infected group’) was diag-
nosed on the basis of positive CSF Gram-stain or
bacteriological culture that was not considered a contam-
inant, or pragmatically in cases that were Gram-stain
negative, on the basis of CSF pleocytosis, elevated serum
inflammatory markers and clinical signs including fever,
meningism and altered consciousness [Infectious Diseases
Society of America (IDSA) guidelines (Tunkel et al.,
2017) and as previously reported (Lozier et al., 2002;
Keong et al., 2012; Jamjoom et al., 2018). The ‘Inflamed
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group’ (chemical meningitis or subarachnoid haemor-
rhage) had a clinically evident inflammatory condition in
whom infection was not diagnosed, and the ‘Control
group’ were patients with normal pressure hydrocephalus
or idiopathic intracranial hypertension undergoing CSF
sampling for management and who had no evidence of
infection or inflammation. For patients in whom intra-pa-
tient variation was measured, subsequent samples during
the infectious or inflammatory episode and subsequent re-
covery were used and analysed separately.
Linked-anonymized clinical data were collected and
stored for subsequent analysis. This included patient
demographics, past medical history, concurrent medica-
tion particularly if immunosuppressant, diagnoses, use
of antibiotics, method of sampling, indication for sam-
pling, serum and CSF cell counts (Hb, white cell counts,
red blood cell (RBC) counts), and the results of the
extended microbiological culture.
Screening of CSF biomarkers
One hundred and eighty-two biomarkers were measured
in 1 ll CSF samples by proximity extension assay by the
Olink Analysis Service at Olink laboratories (Olink
Proteomics AB, Uppsala, Sweden) using pairs of target-
specific antibodies with unique barcoded DNA oligonu-
cleotides contained in the Inflammation I and Neurology
panels (Supplementary Table 2), as per the manufac-
turer’s instructions. Data were normalized to standard
plasma controls and are expressed as normalized protein
expression. Normalized protein expression is a semi-quan-
titative log2 unit which reflects protein concentration but
does not quantify it. Therefore, it is suitable for compari-
sons between samples but is not a definitive quantitation
in itself.
Quantitation of inflammatory mediators was independ-
ently performed in our laboratory with either the
Luminex platform using the manufacturer’s instructions
Table 1 Patient characteristics
Control (n 5 24) Inflamed (n 5 8) Infected (n 5 6)
Mean 6 SD (range) Mean 6 SD (range) Mean 6 SD (range)
M/F 2/22 3/5 4/2
Age 43.5 6 19.5 (21–95) 42.9 6 15.1 (28–67) 43.7 6 8.9 (31–60)
Neurological diagnosis 19 IIH
5 NPH
4 SAH
4 Post-surgical chemical meningitis
• Trigeminal neuralgia
• Epidermoid cyst






Indication for CSF sampling 15 symptom control
9 shunt malfunction
4 SAH-induced hydrocephalus

















Haemoglobin 134 6 27.66 (113–166) 126.4 6 10.3 (111–139) 129.7 6 14.6 (108–146)
Red blood cells 4.86 6 2.80 (3.83–9.5) 4.06 6 0.43 (3.4–4.6) 4.39 6 0.57 (3.52–5.08)
White blood cells 8.05 6 3.92 (5.9–12.6) 9.4 6 1.53 (5.6–11) 13.22 6 5.00 (5.7–22.3)
Neutrophils 5.19 6 3.17 (3.0–9.1) 6.6 6 2.07 (2.1–9.1) 10.1 6 4.87 (3–19.2)







1762.9 6 9103.6 (0–17 558)
3.83 6 19.6 (0–42)
n/a
No organisms seen
No growth on extended cultures
47 547.5 6 110 639.4 (26–339 616)
77.13 6 118.6 (0–384)
17.5 6 23.58 (5–72)
No organisms seen
No growth on extended culture
134 6 150.7 (1–395)
1527 6 2261.3 (11–6480)
89 6 5.79 (81–95)
2 Gram positive cocci
2 coagulase-negative S. aureus
* 4 clinically diagnosed bacterial
infection
Geometric means and SD used for CSF RBC counts. RBC counts were significantly higher in the CSF of inflamed compared to infected patients. CSF white cell counts were signifi-




Other measured parameters were not significantly different between groups.
EVD ¼ external ventricular drain; IIH ¼ idiopathic intracranial hypertension; LD ¼ lumbar drain; LP ¼ lumbar puncture; NPH ¼ normal pressure hydrocephalus; SAH ¼ subarach-
noid haemorrhage; VP ¼ ventriculoperitoneal.
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(CXCL5, CXCL8, CXCL10, extracellular newly identified
receptor for advanced glycation end-products binding
protein (EN-RAGE/S100A12), IL-6, IL-12p40, IL-17, LIF,
OSM; Luminex, R&D Systems) or by enzyme-linked im-
munosorbent assay (IL-23, LegendMax, Biolegend). Each
sample was measured in duplicate.
Pathway analysis
Pathway analysis was performed using ingenuity pathway
analysis (IPA; Qiagen Inc.; Krämer et al., 2014). Given
that our biomarkers are targeted for immune and neuro-
logical responsiveness, they specifically test a subset of
immune and neurological pathways within IPA
(Supplementary Table 3). To prevent subsequent bias,
only those pathways in which 5 or greater of the 182
biomarkers were present in the Olink panel were ana-
lysed. Biomarkers were regarded as being upregulated if
they had a fold change of 2 or greater and a significant
P-value compared to the control group.
To simulate the effect of TLR activation during an in-
flammatory response, only the proteins identified within
IPA as TLR responding were set to their levels in the
infected response and this was overlaid onto the response
in non-infected inflammatory patients. Changes were cas-
caded through the causal networks and pathway analysis
was repeated with the updated protein levels. Pathways
upregulated were then compared to the original pathway
changes occurring in inflamed or infected patients to de-
termine whether this was sufficient to recapitulate differ-
ences between the two patient groups.
Statistical analysis
Statistical analyses and graphing were performed in
Graphpad Prism 8.3.1, Morpheus (https://software.broad
institute.org/morpheus/), and R version 3.6.2. Where mul-
tiple comparisons were performed, Benjamini–Hochberg
correction with a false discovery rate of 5% was used
unless otherwise stated.
To rank biomarkers for potential utility, the mean and
average variation (MAV) score
MAV ¼ xA xB 
nArA þ nBrB
nAþB
was used, where all readings are expressed as log2, and
the two groups for comparison are A and B.
Data availability




Between March 2017 and March 2018, 38 patients pro-
vided informed consent for use of their clinically sampled
serum and CSF for research purposes. As categorized, 24
(63%) were ‘control’ patients, 19 with idiopathic intra-
cranial hypertension and 5 with normal pressure hydro-
cephalus. 15/24 (62.5%) of these patients were shunted
naı̈ve (10 idiopathic intracranial hypertension and 5 nor-
mal pressure hydrocephalus) and 9/24 (37.5%) patients
had either lumbo-peritoneal or VP shunts, none of which
were suspected of infection (Table 1).
In the index group of 14 patients, 8 (21%) were
‘inflamed’ patients (4 with chemical meningitis post-cra-
nial surgery and 4 with subarachnoid haemorrhage) with
no evidence of infection and sterile CSF culture, and 6
(16%) were categorized as ‘infected’ patients (Table 1).
The infected group included two patients whose CSF
showed Gram-positive cocci and in whom coagulase-
negative Staphylococcus spp. infection was confirmed by
Table 2 Potential biomarkers for differentiation between non-inflamed patients, non-infectious inflammation and
infection
Control versus all inflamed/infected patients Inflamed versus infected patients
Biomarker AUC Biomarker AUC Biomarker AUC
IL-6 1.000 EN-RAGE 0.946 IL-17 0.979
OSM 1.000 CCL8 0.946 IL-12p40 0.958
LIF 1.000 CXCL10 0.944 IL-12p70 0.938
CXCL8 0.981 CCL23 0.936 CCL3 0.938
G-CSF 0.978 IL-10 0.936
CCL7 0.975 CXCL6 0.929
CXCL1 0.974 CD6 0.920
MMP-1 0.971 CASP8 0.918
CCL20 0.967 CCL3 0.916
MMP-10 0.963 CXCL5 0.916
CCL4 0.961 CCL13 0.915
CCL2 0.947 CXCL11 0.910
Biomarkers showing significant differences between non-inflamed and inflamed brain, and inflammation due to non-infective and infective causes and corresponding area under the
curve (AUC) for the precision-recall curve.
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extended culture. Four patients did not have culture-posi-
tive CSF but clinical symptoms, serum and CSF markers
(polymorphonuclear leukocytosis) consistent with menin-
gitis/ventriculitis (Tunkel et al., 2017) and were therefore
treated on clinical grounds (Supplementary Table 1).
They included one patient following trans-sphenoidal re-
section of a pituitary adenoma who developed a CSF
leak and subsequent meningitis, one patient with an EVD
in situ for hydrocephalus secondary to a colloid cyst, and
a third patient with meningitis during an admission for
subarachnoid haemorrhage. All three patients were
treated with antibiotics for infection (two lower respira-
tory tracts and one urinary tract) prior to developing
clinical symptoms and signs of meningitis. The fourth pa-
tient presented with a clinically infected pseudomeningo-
cele following a posterior fossa tumour resection and had
already commenced antibiotics. CSF was taken on inser-
tion of a lumbar drain and was turbid in appearance
with 86% polymorphonuclear leucocytosis on
microscopy.
CSF white cell counts were raised significantly in
inflamed patients and raised further in infected patients
(Table 1). However, there was significant overlap be-
tween the groups and hence white cell counts alone was
not sufficiently distinct for diagnostic purposes to dis-
criminate between an inflamed or infective cause.
IL-6 related biomarkers are
elevated in both inflammation and
infection and are correlated to CSF
white cell numbers.
In order to examine differences in soluble proteins pre-
sent in the CSF, we measured 182 neurological and im-
munological biomarkers (Supplementary Table 2) in all
three patient groups. Given the relatively small number
of patients, it was particularly important to reduce the
dimensionality of the data for analysis while retaining
those biomarkers with the potential for effective discrim-
ination between groups. The schema used is shown in
Fig. 1. Initially, biomarker levels were compared between
groups for fold change and significant difference (Fig. 2).
Those which were significant by Mann–Whitney test and
with  2-fold change in expression between any two
groups were retained, reducing the markers to be taken
forward for further analysis to 48 candidates. As a next
step, we used precision-recall curves which give similar
information to a more conventionally used receiver oper-
ating characteristic curve but unlike receiver operating
characteristic curves are not biased by large numbers of
Table 3 Key to Fig. 5.
A IL-17 signalling in fibroblasts
B Role of IL-17 in psoriasis
C IL-17 signalling in airway cells
D IL-17 signalling
E Role of IL-17 in arthritis
F Role of IL-17F in allergic inflammatory airway diseases
G IL-71 signalling in gastric cells
H Differential regulation of cytokine production in macrophages
and T helper cells by IL-17 & IL-17F
I Th17 activation pathway
J Differential regulation of cytokine production in intestinal epi-
thelial cells by IL-17 and IL-17F
K Role of hypercytokinaemia/hyperchemokinaemia in the patho-
genesis of influenza
L Chemokine signalling
M Agranulocyte adhesion and diapedesis
N Granulocyte adhesion and diapedesis
O TREM1 signalling
P Toll-like receptor signalling
Q Activation of IRF by cytosolic pattern recognition receptors
R Pathogenesis of multiple sclerosis
S Type I diabetes mellitis signalling
T Adrenomedullin signalling pathway
U Systemic lupus erythematosus in T cell signalling pathway
V Dendritic cell maturation
W Acute phase response signalling
X LXR/RXR activation




Figure 1 Plan of feature selection.
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correctly classified negative control samples. This was an
important consideration given that there were more
patients in the control group than within other individual
groups. Retaining only those biomarkers that showed an
area under the precision-recall curves of 0.9 and above,
the number of potentially relevant biomarkers was
reduced further to a total of 28 proteins.
Overall, the biomarkers that were increased in inflamed
and infected patients were very similar, with differences
mainly occurring in the relative amount of each biomark-
er present rather than their identity (Fig. 2A and B). To
find differences of potential diagnostic relevance between
inflamed and infected patients despite this substantial
overlap, a two-stage process was used in which inflamed
and infected samples were combined and treated as one
group compared to controls, and then the infected and
inflamed groups were compared to one another as a se-
cond step (Fig. 2C and D). This two-stage process
resulted in 28 markers showing differences between con-
trol and all infected/inflamed patients as described above
(Fig. 3, Table 2). The most clearly differentiating bio-
marker between control patient samples and either
bacterial infection or non-bacterial inflammation was IL-
6. While the IL-6 related cytokines leukaemia inhibitory
factor (LIF) and oncostatin M (OSM) appeared to have
similar fold increases in concentration when looking at
the aggregate data (Fig. 2), these were more variable
when individual patient data were examined (Fig. 3).
However, for all three biomarkers, levels were indistin-
guishable between infected and inflamed patients.
Given that CSF inflammation was associated with both
an increase in inflammatory cytokines and increased
leukocyte counts, we hypothesized that the two would be
correlated and quantitated the most relevant proteins
using the Luminex platform. Indeed, the amounts of the
IL-6 related proteins were strongly correlated to cell num-
bers (Fig. 4). Similarly, the neutrophil-derived biomarker
extracellular newly identified receptor for advanced glyca-
tion end-products binding protein (EN-RAGE/S100A12)
had a clear association with infiltrating cells, reflecting
the large number of neutrophils attracted into the sites
after damage (R2 ¼ 0.3208). The chemokine CXCL10
had a monotonic relationship with cell number (R2 ¼
0.3338), which was present but weaker for CXCL8 (R2
Figure 2 Differential levels of proteins in the CSF. Each protein assayed is indicated by an individual data point, with larger fold change in
protein levels indicated by colour and size. Those with particularly large fold changes are most likely to be significant and are labelled. Horizontal
line represents the Benjamini–Hochberg critical value at which statistical significance is achieved.
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¼ 0.0878), consistent with their roles in attracting im-
mune cells into sites of damage and inflammation.
A distinct biomarker signature in
cerebrospinal fluid identifies
bacterial infection
Importantly, this two-stage process resulted in a subset of
four markers showing differences between bacterially
infected and non-specifically inflamed patients (Figs 2 and
3). Comparison of the inflamed and infected patients
showed that CSF levels of IL-17, IL-12p40 and IL-12p70
successfully differentiated the two groups, with CCL3
showing lesser difference (Table 2). Interestingly, CCL20,
CCL8 and granulocyte-colony stimulating factor, which
were amongst the most differentiating biomarkers be-
tween controls and infected patients (Fig. 2B), were not
statistically different between infected and inflamed
patients, as shown by their relatively high P-values and
correspondingly low log10 P-values (Fig. 2D).
In contrast to IL-6 and related cytokines, IL-12p40 and
IL-17 levels were not associated with infiltrating cell
numbers, supporting a different aetiology for their pro-
duction independently of the number of immune cells
entering the site of inflammation (Fig. 4). Given that the
IL-12p40 subunit is common to the dimeric cytokines IL-
12p70 and IL-23, and the importance of the IL-17/IL-23
axis in neuroimmunology, we also quantitated IL-23 in
patient samples. Similar to IL-12p40 and IL-17, IL-23
Figure 3 Protein levels of biomarkers in the CSF. Heat map showing relative amounts of immunological biomarkers in response to
inflammation or infection compared to control patients. Higher concentrations of immunological biomarkers are indicated in red; lower
concentrations are indicated in increasing blue intensity.








s/article/2/2/fcaa218/6040731 by guest on 18 January 2021
levels were not correlated with the number of immune
cells in the CSF (Fig. 4).
Of note, measurement of serial samples in two control
patients, one patient during and after chemical meningitis,
and two patients during and after bacterial infection
showed that none of these biomarkers changed with
time, reinforcing the hypothesis that these markers were
specific to infection and inflammation and not simply
artefacts of variability between patients (Supplementary
Fig. 1).
IL-17 pathways are stimulated in all
inflammation, but IL-17 levels are
raised specifically during bacterial
infection in response to TLR
activation
To examine the underlying biology of the responses,
pathway analyses were performed on the data. Changes
in protein levels were compared between infected versus
control groups, inflamed versus control groups and
infected versus inflamed groups for all biomarkers with a
significant P-value and greater than 2-fold change.
Perhaps unsurprisingly given the sharing of many bio-
markers between infection-related and non-infective in-
flammation (Supplementary Fig. 2), the identities of the
pathways induced was broadly similar. Biomarkers found
to be at increased concentrations in inflamed and infected
patients were overwhelmingly found to contribute to IL-
17-associated pathways, IL-6-associated inflammation and
cell movement (Fig. 5A and B). All pathways upregulated
were dominated by chemokines (Supplementary Table 3).
The most significant difference between inflamed and
infected patients was in the induction of the TLR signal-
ling pathway (Fig. 5B, column P) in which five of six
proteins assayed were induced in infected patients com-
pared to only one in inflamed patients. Given that many
of the pathways shared common biomarkers, it was pos-
sible that induction of TLR signalling was artificially
causing other pathways to appear to be induced in
infected patients. To test this, the six biomarkers identi-
fied by the IPA pathway analysis program as being re-
sponsive to TLR stimulation were set to the higher levels
seen in infected patients. These were then overlaid onto
the response to inflammation in inflamed patients to
simulate TLR activation in an inflamed environment, and
the pathway analysis was repeated. The simulated TLR
response was then compared to the response in infected
patients. These calculations demonstrated unambiguously
that adding the biomarkers associated with a TLR re-
sponse to the biomarkers associated with the underlying
inflammation in the inflamed patients recapitulated the
pattern of pathway stimulation seen in the infected group
(Fig. 5C). Overall, these data strongly support the re-
sponse to the infection being characterized by an inflam-
matory response, which is augmented by TLR activation.
Upstream causal network analysis showed peptidogly-
can to be the most likely upstream regulator in bacterial-
ly infected patients (P¼ 5.87  1036). Peptidoglycan is a
component of the outer wall of bacteria which can be
recognized by pattern recognition receptors such as TLR2
(Kielian et al., 2005; Wolf and Underhill, 2018). This
contrasted with the upstream regulators in inflammation
which were overwhelmingly cytokines: IL-17F (P¼ 1.05
 1030), IL-1a (P¼ 4.23  1030) and IL-4 (P¼ 1.68 
Figure 4 Correlation between white cell count in the CSF and soluble biomarkers. Cytokines shown were quantified by enzyme-
linked immunosorbent assay (IL-23) or luminex (all other) and analysed using log-log regressions.
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1029). Together, the pathway analyses support TLR acti-
vation by peptidoglycan as the dominant pathway leading
to increased inflammatory markers in infection compared
to non-infectious inflammation.
An efficient biomarker signature
can be created from immune
molecules present in the CSF
To define a potential signature for diagnostic discrimin-
ation between non-bacterial inflammation and bacterial
infection, biomarkers were ranked by comparison of their
difference between means with averaged variation in sub-
groups (mean and average variation score). This was per-
formed both for the discrimination between controls
versus all inflamed and infected patients pooled together,
and for the specific discrimination between inflamed ver-
sus infected patients. For validation of the raised levels in
the Olink proximity extension assay, the absolute levels
of the three proteins yielding the highest scores in each
category were quantitated by Luminex or enzyme-linked
immunosorbent assay and compared between groups as
candidate signature molecules for discriminating inflam-
mation and infection. Interestingly, while LIF had a
receiver operating characteristic area under the curve of 1
absolute levels of LIF were very small, resulting in a low
mean and average variation score that reflected its im-
practicality as a biomarker. In accordance with the rela-
tive biomarker levels determined by Olink analysis,
absolute amounts of IL-6, OSM and CXCL8 were effect-
ive indicators of inflammation without discriminating be-
tween bacterial and non-bacterial causes of inflammation
(Fig. 6). IL-6 was capable of distinguishing patients with
inflammation (bacterial or non-bacterial) from control
patients with a sensitivity and specificity of 100%; OSM
with a sensitivity of 92.9% and specificity of 93.8%; and
CXCL8 with a sensitivity of 85.7% and specificity of
100%. In contrast, elevated levels of IL-17, IL-23 and IL-
12p40 were capable of predicting infection specifically,
with IL-17 (100% sensitivity and specificity) more effect-
ive than IL-23 (83.3% sensitivity, 100% specificity) and
IL-12p40 (83.3% sensitivity, 85.7% specificity) for this
cohort. Taken together, these findings support a potential
biomarker signature of diagnostic relevance, consisting of
raised IL-6, OSM and CXCL8 in the CSF for detecting
general CNS inflammation, and additional raised IL-17
as well as IL-12p40 or IL-23 as indicative of a bacterial
cause for the inflammation. As the functional IL-23 cyto-
kine contains the IL-12p40 subunit, we speculate that for
practical reasons it will be sufficient, and arguably more
specific, in future studies to measure directly IL-23 in-
stead of IL-12p40.
Discussion
In this study, we investigated a panel of 182 immune
and neurological markers using advanced IPA pathway
analysis and identified a biomarker signature distinguish-
ing nosocomial infection from neuroinflammation, based
on the biologically plausible pathway of TLR activation
by bacterial cell wall products. If validated in a larger
clinical study, this signature could be of significant value
for allowing rapid point of care diagnosis of infections,
facilitating the difficult task of determining whether a pa-
tient will benefit from antibiotics or require a different
therapy. This study also gives an intriguing insight into
early pathways differentially activated by sterile inflam-
mation and nosocomial infection, both converging on a
common downstream inflammatory response which may
explain many of the previous difficulties in distinguishing
these important conditions and points to the potential
utility of biomarker strategies targeting early differential
initiating pathways.
While limited patient numbers mean that our study
does not have sufficient statistical power to definitively
describe the biomarkers and their specificities and sensi-
tivities, our pathway analyses strongly support that the
responding biomolecules represent real differences in the
underlying biology between the groups rather than false-
positive readings. Further, the inclusion of a wide range
Figure 5 Pathways potentially stimulated in CNS
inflammation and infection. (A) Pathways upregulated in
infected patients compared to control patients. (B) Pathways
upregulated in patients with CNS inflammation compared to
control patients. (C) The resultant pattern of pathway stimulation if
the proteins increased in the TLR pathway are added into the
biomarkers responding in inflamed patients. Inflamed response
shown in darker colours superimposed on the response to
inflammation with the response to TLR stimulation added in paler
colours. Labels A to AB on the x-axis refer to the pathways shown
in Table 3.
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of mixed pathologies supports that the responding bio-
molecules represent real differences and commonalities in
the underlying biology between the diverse groups, mak-
ing diversity a strength of the study. The value of the
study is both in its examination of a wide battery of bio-
markers to aid pathway analysis and in its selection of
CSF samples taken at the time of clinical equipoise for
the early diagnosis of nosocomial infection from a wide
background of clinical pathologies. CSF analysis is un-
avoidably skewed by the clinical decision to sample, and
the equipoise examined can remain after the initial CSF
cell counts are available while definitive microbiological
culture is awaited. This is indicative of the real-world
clinical difficulty, unlike that examined in many studies
which seek to diagnose nosocomial infection either purely
on the basis of CSF examination, the sampling timing of
which is not clear relative to the diagnostic equipoise
(Beer et al., 2008; Mu~noz-Gómez et al., 2015; Sorinola
et al., 2019; Zheng et al., 2020) or later purely on a lim-
ited number of biomarkers analysed post hoc (van
Mourik et al., 2012, 2015). The multiple pathologies we
encountered are also reflective of clinical practice where
the ultimate goal is to achieve diagnostic resolution of
nosocomial infection against the complete spectrum of
non-infective aetiologies encountered in neurosurgical and
neurological care.
As an accurate diagnosis of nosocomial infection in all
cases is so challenging (Dorresteijn et al., 2019), we, like
others, chose a pragmatic approach of either bacteria
seen on Gram stain or positive bacteriological culture or
a highly suggestive clinically picture with supportive CSF
pleocytosis and a response to antibiotic treatment. In our
study, the utility of examining additional CSF biomarkers
at the point of equipoise after initial CSF analysis is the
pertinent question and the accuracy or otherwise of the
initial clinical impression is secondary to the primary
comparison of the eventual outcomes with the CSF bio-
marker pattern and pathway analysis.
Elevated CSF levels of IL-6 have been well described in
studies of community-acquired bacterial meningitis
(Prasad et al., 2014; Garcı́a-Hernández et al., 2016;
Srinivasan et al., 2016; Lepennetier et al., 2019; Liba
et al., 2019), but not in all (Asano et al., 2010), and IL-
6 is also raised in encephalitis (Morichi et al., 2018).
Elevated IL-6 levels in CSF have not only been reported
in nosocomial infections in patients with shunts and
EVDs (Asi-Bautista et al., 1997; Schoch et al., 2008;
Lenski et al., 2019, Skar et al., 2019b) but also in in-
flammation and vasospasm after subarachnoid haemor-
rhage (Lenski et al., 2017), all combining to make it a
poor differentiator between nosocomial infection and ster-
ile neuroinflammation. EN-RAGE is produced by
Figure 6 Quantitation of biomarkers. Biomarkers were measured in CSF by Luminex or enzyme-linked immunosorbent assay, and results
were compared by Kruskall–Wallis followed by Dunn’s multiple comparisons test. * P< 0.05, ** P< 0.01, *** P< 0.001.
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macrophages in response to IL-6 in vitro (Hasegawa
et al., 2003), and both EN-RAGE and IL-6 (Chiaretti
et al., 2008) have previously been noted as increased in
serum or CSF, respectively, in response to cerebral
trauma and during paediatric CNS infection when com-
pared to controls (Prasad et al., 2014; Garcı́a-Hernández
et al., 2016). Given that production of IL-6 is a broad re-
sponse to both trauma and immunological challenge, it is
not surprising that it is elevated irrespective of whether
CNS damage is sterile or induced by a bacterial or viral
infection. This is all consistent with our findings of ele-
vated IL-6 levels in both inflamed and infected groups
and our pathway analysis identifying downstream IL-6
elevation in both groups.
Elevated CSF IL-17 has been reported in bacteriological
CNS infections (Asano et al., 2010; Prasad et al., 2014),
and in influenza-associated encephalopathy and convul-
sions following gastroenteritis (Morichi et al., 2018). A
single study has reported a non-significant trend to
increased IL-17 CSF levels in nosocomial shunt related
CSF infections (Skar et al., 2019b). Here we show that
IL-17 is particularly promising for differentiating infection
from sterile inflammation, and the addition of variables
such as IL-23 and IL-12p40 may further improve this dif-
ferentiation. It is worth noting that generic IL-17 path-
ways were upregulated in both inflammation and
infection despite IL-17 levels near or even below the en-
zyme-linked immunosorbent assay /Luminex detection
limit in inflamed patients, in contrast to the higher levels
found in bacterially infected patients. The upregulation of
the generic IL-17 pathways in inflamed patients is instead
indicated by increases in the chemokines that accompany
IL-17 in the pathway. In contrast, increased IL-17 as an
indicator of bacterial infection occurred in addition to the
biomarkers increased in the canonical TLR pathways
used in this study (see Supplementary Table 3). The
source of IL-17 may include Th17 cells although four out
of six IL-17 high patients in the present study had pre-
dominantly neutrophil responses in the CSF, which occur
typically prior to optimal T cell responses. The pattern of
accompanying cytokines and chemokines in fact suggests
that IL-17 may alternatively derive from activated astro-
glial cells (Waisman et al., 2015) or resident cd T cells
(Ribeiro et al., 2019).
The finding that IL-23 is upregulated in the same
patients as IL-17 is consistent with an overall stimulation
of the IL-23/IL-17 axis, which has previously been found
to be activated by peptidoglycan (Tyler et al., 2017).
Mouse studies have identified IL-23 as an important
regulator in inducing IL-17 (Shichita et al., 2009; Sutton
et al., 2009; Gelderblom et al., 2018) and some forms of
CNS inflammation (Cua et al., 2003; Sutton et al., 2009;
Gelderblom et al., 2018) in experimental systems. In
patients, elevated IL-23 in CSF has been found in paedi-
atric meningitis patients (Srinivasan et al., 2018). While
the authors of that study did not measure IL-17 or com-
pare with sterile inflammation, the data are supportive of
the hypothesis that the IL-17/IL-23 axis is broadly upre-
gulated in patients with meningitis, as is a large hospital
study into meningitis (albeit without comparing to unre-
lated inflammation) (Liu et al., 2020). Our data form an
important adjunct to the preclinical literature, showing
that these findings are also likely to be relevant during
human disease and linking studies which have examined
the cytokines.
Our findings define an innate immune response to dam-
age in the CSF of all patients with inflammation, which is
overlaid with a TLR-stimulated response in the case of
bacterial infection. The TLR response that was evident in
bacterially infected patients is consistent with the reported
expression of TLRs on microglia, oligodendrocytes and
astrocytes (Bsibsi et al., 2002; Jack et al., 2005). TLRs
are a family of evolutionarily ancient pattern recognition
receptors which can recognize damage-associated molecu-
lar patterns and pathogen-associated molecular patterns,
including lipoproteins and peptidoglycan from the outer
surface of Gram-positive organisms such as
Staphylococcus spp. Coagulase-negative staphylococci
were identified in both patients in whom bacterial culture
was successful, and are known to be a common cause of
medical implant and shunt infection (Becker et al., 2014;
Jamjoom et al., 2018; Mallucci et al., 2019). The path-
way analysis used in IPA indeed showed that TLRs are
likely to be important in the induction of the cytokines
and chemokines observed. Given the potential of peptido-
glycan (Tyler et al., 2017) and S. aureus extracts
(Zielinski et al., 2012) in upregulating IL-23 expression in
monocytes and DCs and priming T cell responses, there is
a potential pathway of action occurring in these patients
that merits further biological validation.
In terms of defining potential biomarkers, previous
studies identified CXCL8 and tumour necrosis factor-a as
potentially useful in determining whether patients have
bacterial CNS infection (Mukai et al., 2006; Hsieh et al.,
2009; Pinto Junior et al., 2011; Garcı́a-Hernández et al.,
2016; Srinivasan et al., 2016, 2018), although none of
these were sufficiently predictive for differentiating infec-
tion from inflammation. While a comprehensive review is
outside the scope of this study, it is worth highlighting a
complementary approach to ours of examining inflamma-
tory markers at the terminal pathways for bacteriological
attack, such as the complement system’s soluble mem-
brane attack complex (sMAC) (Ramos et al., 2016).
Although that study showed that sMAC levels above a
43 ng/ml had a sensitivity and specificity of 93% and
86%, respectively, with area under the curve 0.966 for
diagnosing pyogenic infections in children, it was much
poorer at identifying low-grade commensal pathogens
such as Staphylococcus spp. or Propionibacterium acnes
infection which are a more frequent cause of nosocomial
infections in adults with shunts, and the examined clinical
pathologies were confined to infection. Another promising
approach is to use markers of neutrophils, macrophages
and mature monocytes as they infiltrate the brain during
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infection by examining soluble triggering receptor
expressed on myeloid cells (TREM)-1 in the CSF
(Gordon et al., 2014), which showed a 100% sensitivity
and 98% specificity for diagnosing EVD bacterial ventri-
culitis. However, their study did not attempt to distin-
guish infective from non-infective inflammation, and
standard CSF glucose levels performed as well as
sTREM-1.
Conclusion
In contrast to previous studies, we examined a wide bat-
tery of inflammatory and neurological markers allowing
pathway analysis across a spectrum of challenging pathol-
ogies which generate sterile neuroinflammation against
which nosocomial infection is extremely challenging to
diagnose. Within our data, the most reliable signature for
non-bacterial inflammation was high levels of IL-6 with
low levels of IL-17, and the most reliable signature for
bacterial infection was high levels of IL-6 with high levels
of IL-17. Notably, IL-6 could not distinguish between
bacterial and non-bacterial inflammation. Pathway ana-
lysis provided a biologically plausible explanation of dif-
ferential upstream initiation in infection by TLR
signalling via IL-17 in addition to common IL-6 associ-
ated inflammation in sterile neuroinflammation. This is
the first study in patients to demonstrate biomarkers dis-
tinguishing infection from background neuroinflamma-
tion, and to use accompanying data to investigate which
pathways are responsible. The data are especially relevant
to the commonly encountered pathologies such as sub-
arachnoid haemorrhage and post-cranial neurosurgery for
diagnosing secondary nosocomial infection. Given vari-
ability within populations, the IL-6 and IL-17 markers
are more likely to be robust if combined into a metric
also including OSM and IL-23. If replicated in a larger
study these findings could find immediate clinical utility
for the bedside diagnosis of infected CSF with significant
improvements in patient care and outcomes. Point-of-care
lateral flow devices, such as the one recently developed
for diagnosing peritonitis (Goodlad et al., 2020), would
permit bedside diagnosis within minutes leading to a po-
tential step change in the care of neurological infection.
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